Cited by 1,806Adipokines, Inflammation, and Metabolic DiseasesAdipose Tissue and MetabolismCardiovascular Disease and Adiposity

Obesity, Inflammation, and Insulin Resistance

Shoelson, Steven E., Herrero, Laura, Naaz, Afia·2007·Gastroenterology

Abstract

Weight gain and obesity are major risk factors for conditions and diseases ranging from insulin resistance and type 2 diabetes mellitus to atherosclerosis and the sequelae of nonalcoholic fatty liver disease. A chronic, subacute state of inflammation often accompanies the accumulation of excess lipid in adipose tissue and liver (hepatic steatosis), evidenced by changes in both inflammatory cells and biochemical markers of inflammation. These changes can be seen in the involved tissues and systemically, in terms of elevated circulating levels of inflammatory markers. The link between obesity and inflammation has therefore raised the important question of whether obesity-induced inflammation plays a pathogenic role in the development and progression of these disorders. We review the rapidly expanding body of animal and clinical data that support potential roles for inflammation in the pathogenesis of insulin resistance and type 2 diabetes mellitus.

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2007.03.059

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Obesity is related to a low-grade inflammation, and increased production and secretion of inflammatory factors including TNF-α and IL-6 modulate insulin sensitivity by altering key steps in the insulin signaling pathway, which is responsible for subsequent insulin resistance.

    “Meanwhile, obesity is related to a low-grade inflammation, the increased production and secretion of multifarious inflammatory factors including TNF-α, IL-6 modulate insulin sensitivity by altering some key steps in the insulin signaling pathway, which is responsible for the subsequent insulin resistance (34–36).”
  • Adipocytes are the unique source of secreted adipokines such as leptin and adiponectin, which can promote insulin sensitivity, and resistin and retinol-binding protein 4, which can impair insulin sensitivity.

    “Adipocytes are the unique source of secreted adipokines such as leptin and adiponectin, which can promote insulin sensitivity, as well as resistin and retinol-binding protein 4 (RBP4), which can impair insulin sensitivity (83)(84)(85).”
  • Elevated levels of TNF-α, IL-6, and C-reactive protein have been shown in individuals with insulin resistance and diabetes.

    “Consistent with this, elevated levels of the proinflammatory cytokines TNF-α, IL-6, and C-reactive protein (CRP) have been shown in individuals with insulin resistance and diabetes (for review, see refs.[83][84][85].”
  • Several cytokines and chemokines, including CCL2, IL-6, IL-1β, MIF, and TNF-α, can be released by adipocytes and macrophages.

    “Several cytokines and chemokines, such as CCL2, IL-6, IL-1β, macrophage migration inhibitory factor (MIF), and TNF-α, can be released by adipocytes and macrophages (83)(84)(85).”
  • Inflammation lies at the heart of many of these processes, and pathways involving NF-κB are especially core.

    “inflammation lies at the heart of many of these processes, and pathways involving NF-κB (see e.g. http://www.nf-kb.org/) are especially core here”

The citation lists haven’t been fetched yet

References 145 · Cited by 1,806

Authors
Shoelson, S. E., Herrero, L., & Naaz, A.
Affiliations
Joslin Diabetes Center (US)
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2007-05
Volume
132
Issue
6
Pages
2169-2180
ISSN
0016-5085 (ISSN-L)
OpenAlex
W1975537939
Cited by
1,806
References
145
Citations by year
2026: 33 · 2025: 71 · 2024: 71 · 2023: 72 · 2022: 104 · 2021: 111 · 2020: 103 · 2019: 83 · 2018: 77 · 2017: 101 · 2016: 110 · 2015: 110 · 2014: 113 · 2013: 118 · 2012: 114
FWCI
12.07
Type
journal article
Language
en
Open access
closed
Locations
  • Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5p50hl083813-05)
  • National Heart, Lung, and Blood Institute (HL83813)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK 51729, U01DK074556, DK 45943, R01DK045943, R01DK073547, R01DK043123, DK 43123, DK73547, DK74556)
Topics
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Physiology › Adipose Tissue and Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
Keywords
obesity, inflammation, insulin resistance, type 2 diabetes, adipose tissue, hepatic steatosis, non-alcoholic fatty liver disease, atherosclerosis, inflammatory markers, pathogenesis
MeSH terms
Adipose Tissue, Animals, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Humans, Inflammation, Insulin Resistance, Obesity, Risk Factors, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review